Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4406-4412

  Van Erp, Nielka P ^a   Eechoute, Karel ^a   Van Der Veldt, Astrid A ^a   Haanen, John B ^a   Reyners, An K L ^a   Mathijssen, Ron H J ^a   Boven, Epie ^a   Van Der Straaten, Tahar ^a   Baak Pablo, Renée F ^a   Wessels, Judith A M ^a   Guchelaar, Henk Jan ^a   Gelderblom, Hans ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD135 ANTIGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; NR1I2 PROTEIN; NR1I3 PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; PROTEIN RET; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG METABOLISM; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAND FOOT SYNDROME; HAPLOTYPE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEOPLASM; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP1A1; DRUG TOXICITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDOLES; LEUKOPENIA; MALE; MIDDLE AGED; MUCOSITIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; RISK FACTORS; YOUNG ADULT;

EID: 70349342710     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.7679     Document Type: Article

References (36)

1. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
2. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
3. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
4. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007
5. Chu TF, Rupnick MA, Kerkela R, et al: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019, 2007
6. Goodman VL, Rock EP, Dagher R, et al: Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373, 2007
7. Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187, 2005
8. Faivre S, Demetri G, Sargent W, et al: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745, 2007
9. van der Veldt AAM, Boven E, Helgason HH, et al: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259-265, 2008
10. Adams VR, Leggas M: Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29:1338-1353, 2007
11. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
12. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007
13. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
14. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83, 2007
15. Schmidinger M, Zielinski CC, Vogl UM, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212, 2008
16. Cancer Therapy Evaluation Program: Common Toxicity Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov
17. Shukla S, Robey RW, Bates SE, et al: Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359-365, 2009
18. Harmsen S, Meijerman I, Beijnen JH, et al: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: A key role for the pregnane X receptor. Cancer Chemother Pharmacol 64:35-43, 2009
19. Li J, Zhao M, He P, et al: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737, 2007
20. van Erp NP, Gelderblom H, Karlsson MO, et al: Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13:7394-7400, 2007
21. Bhojani N, Jeldres C, Patard JJ, et al: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917-930, 2008
22. Hutson TE, Figlin RA, Kuhn JG, et al: Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 13:1084-1096, 2008
23. Aarnoudse AJ, Dieleman JP, Visser LE, et al: Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 18:299-305, 2008
24. Hoffmeyer S, Burk O, von RO, et al: Functional polymorphisms of the human multidrugresistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-3478, 2000
25. Saitoh A, Sarles E, Capparelli E, et al: CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21:2191-2199, 2007
26. Fukui N, Suzuki Y, Sawamura K, et al: Dosedependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 29:185-189, 2007
27. Cascorbi I: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473, 2006
28. Mathijssen RH, Marsh S, Karlsson MO, et al: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253, 2003
29. Rudin CM, Liu W, Desai A, et al: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127, 2008
30. Lamba J, Lamba VSchuetz E: Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6:369-383, 2005
31. Wang Y, Zheng Y, Zhang W, et al: Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50:760-767, 2007
32. Carow CE, Levenstein M, Kaufmann SH, et al: Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87:1089-1096, 1996
33. Nakao M, Yokota S, Iwai T, et al: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911-1918, 1996
34. Stram DO, Haiman CA, Hirschhorn JN, et al: Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55:27-36, 2003
35. Epstein MP, Satten GA: Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 73:1316-1329, 2003
36. Purcell S, Neale B, Todd-Brown K, et al: PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559-575, 2007